Novo Nordisk and the University of Toronto announced that they will make a joint investment of 238 million TL for the prevention of diabetes and chronic diseases. Within the framework of the cooperation, the 100th Anniversary of the discovery of insulin will also be celebrated. Two institutions will collaborate again 100 years later to improve the lives of people living with diabetes and prevent Type 2 diabetes
Novo Nordisk announced that an investment of 238 million TL will be made for the establishment of the Healthy Society Network together with the University of Toronto. The project will focus on new methods to support healthier urban populations. The collaboration will leverage the university’s expertise in public health research and training programs to support the global fight against diabetes and other serious chronic diseases. The new network will be headquartered at the University of Toronto, Mississauga; The Dalla Lana School of Public Health will be established in collaboration with the Temerty School of Medicine and the University of Toronto Mississauga.
Insulin was discovered in 1921 at the University of Toronto by a research team consisting of Frederick Banting, Charles Best, JJR MacLeod, and James Bertram Collip. Novo Nordisk was among the first to manufacture insulin on a large scale and has launched this life-saving treatment from the University of Toronto labs around the world. 100 years later, the University of Toronto and Novo Nordisk will collaborate again to improve the lives of people living with diabetes and prevent type 2 diabetes.
Meric Gertler, President of the University of Toronto, said: “We are excited to once again collaborate with Novo Nordisk as we celebrate the 100th anniversary of the discovery of insulin. Novo Nordisk is a company that recognizes the importance of helping those living with diabetes and other serious illnesses. These historic investments will provide research and training opportunities for the university. “It will pool the expertise of our healthcare partners and make a real difference for people battling chronic disease, not just in Canada but around the world.”
“Our company’s goal of defeating diabetes, obesity and other serious chronic diseases requires much more than just innovative medicines,” said Lars Fruergaard Jørgensen, CEO and President of Novo Nordisk.
“100 years after the discovery of insulin, we are proud to once again partner with the University of Toronto to help society address the root causes of type 2 diabetes and obesity. We celebrate the success of insulin in saving millions of lives around the world and expand our commitment to the prevention of these serious chronic diseases.”
The investment of 119 million TL to be made by Novo Nordisk will be supported by Toronto University with financial aid of 119 million TL. Novo Nordisk is also making an additional donation of approximately TL 12 million to the University of Toronto’s Banting and Best Diabetes Center to support research and honor the work of Banting and Best.
Novo Nordisk Vice President and Turkey General Manager Dr. Burak Cem made the following statement on the subject:
“2021 marks a historic milestone for the life-saving molecule Insulin. At Novo Nordisk, we have the honor of working for a company built on the legacy of the insulin molecule, our core mission is to beat diabetes. In this direction, the cooperation with the University of Toronto in a global sense is very exciting for us. Our company, managed by the world’s largest foundation, was established with a lofty goal and with this goal, it improves the lives of approximately 33 million patients every year and acts with an innovative perspective, focusing on development.
Many countries want to bring some of the production of Novo Nordisk, which is managed by the world’s leading insulin producer and the world’s largest foundation, to their countries. We, as Novo Nordisk Turkey, are working hard to step forward and attract investment to our country in this difficult period. With this investment we plan to strengthen our presence in Turkey, we envisage employing 200 people, doubling our clinical work, positioning Turkey as a logistics center and at the same time making it a management center where 77 countries are managed. To this end, we are in talks with various organs of our state. We hope that our efforts for local investment will surpass other countries and we can achieve our goal of becoming a production and strategic center in Turkey.”
Source: (BHA) – Beyaz News Agency
